Topics covered in this NUCATS Institute seminar included:

• The NIH Rapid Access to Interventional Development (RAID) Pilot Program: a drug development resource for ANY disease
• High level overviews of other, more disease focused drug development programs at NIH, including the slightly different NCI-RAID program
• Key differences between the programs – what is and is not offered
• Why the programs exist – the daunting process of getting a new drug to the clinic
• What to think about when putting together proposals
• And more!

Materials from the presentation

Access archived presentation (free registration required)

Review the slide deck ( 303kb)

View a two page summary of the RAID program ( 479kb)

 
About the Presenter:

David G. Badman, PhD, Program Officer, NIH RAID Pilot Program

Dr. Badman was Assistant Professorof Biology, Kalamazoo College 1969-1974, and joined the NIH in 1974. He directed the Hematology Program of the National Institute of Diabetes and Digestive and Kidney Diseases, where he managed a portfolio of blood-related research grants amounting to approximately $70 million in FY 2004. The program’s emphasis was basic red blood cell research, hemoglobin disorders, iron metabolism, and stem cell biology, supported by research grants, Center grants, and SBIR awards. He was Project Officer for the Iron Chelator Drug Development Program of the NIDDK from 1976-2004. Dr. Badman was appointed Deputy Director of the Division of Kidney, Urologic and Hematologic Diseases of the NIDDK in 1999, where he had direct responsibility for the Division research budget, and advised the Director, DKUHD, on policy and administrative matters. He received numerous awards, including 2 NIH Director’s awards, and an NIDDK Director’s award. He retired from the Federal Civil Service in December, 2004. He currently is contracted to the NINDS, where he is the Program Officer for the NIH-RAID Pilot, a Roadmap program designed to assist academic investigators in developing therapeutic agents.

About the NIH-RAID Pilot Program:

The NIH-RAID Pilot Program is intended to reduce some of the common barriers between laboratory discoveries and clinical trials of new therapeutic entities. The program can be utilized for a number of things, from cGMP synthesis and scale up of compounds, to toxicology and pharmacokinetic testing, to preclinical testing of biologics, to help with preparation of an IND. NIH-RAID differs from traditional funding mechanisms in that investigators are not directly awarded funds, but instead given access, at no cost, to the National Cancer Institute Developmental Therapeutics Program’s contractor resources.
 

NUCATS is pleased to partner with the Robert H. Lurie Comprehensive Cancer Center and the Center for Drug Discovery and Chemical Biology in producing this event.